- Home
- VXRT
VXRT
Vaxart Inc
as 07-26-2024 4:00pm EST
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Vaxart Inc VXRT prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 122.4M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $1.54 | Next Earning Date: | 08-01-2024 |
| Revenue: | $8,885,000 | Revenue Growth: | 1174.75% |
| Revenue Growth (this year): | 104.04% | Revenue Growth (next year): | 47.46% |
Stock Insider Trading Activity of Vaxart Inc (VXRT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watson W. Mark | VXRT | Director | Jun 18 '24 | Buy | $0.68 | 20,000 | $13,578.00 | 78,125 | SEC Form 4 |
Latest Vaxart Inc News
VXRT Breaking Stock News: Dive into VXRT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most
GlobeNewswire
a month ago
Vaxart Provides Business Update
Benzinga
a month ago
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
MT Newswires
a month ago
Vaxart Receives $453 Million for Phase 2b Trial of Covid-19 Oral Pill Vaccine Candidate
MT Newswires
a month ago
Vaxart Launches $40 Million Share Offering; Shares Rise Pre-Bell
GlobeNewswire
a month ago
Vaxart Announces $40 Million Underwritten Offering of Common Stock
GlobeNewswire
a month ago
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
GlobeNewswire
2 months ago
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare VXRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VXRT Vaxart Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.